HomeSuppliersPeptide LibraryCompareBlog⚠️ BlacklistHow it worksLog in
HomePeptide libraryPT-141

PT-141Strong clinical evidence

Bremelanotide

A synthetic cyclic analog of alpha-MSH; FDA-approved as Vyleesi for hypoactive sexual desire disorder in premenopausal women.

⚙️ How it works

A non-selective melanocortin receptor agonist acting mainly on MC4 (and MC3) receptors in the hypothalamus and limbic arousal pathways. Unlike PDE5 inhibitors that work on peripheral blood flow, it modulates the central neural circuitry that generates desire itself, with downstream dopaminergic signalling.

🎯 What it's studied to help

Bars reflect the strength & volume of research evidence for each use — not a guarantee of results.

Libido90/100
Activates central melanocortin pathways that drive desire/arousal; large Phase 3 trials and FDA approval.
Central melanocortin/dopaminergic modulation is loosely linked to motivation; evidence is indirect.

✍️ Share your experience with PT-141

Verify to leave a review
Sign in once (Google or email) so reviews stay genuine — one review per person, editable anytime.
Sign in to review

⭐ Reviews (0)

No reviews yet. If you've used PT-141, be the first to share what it helped with and any side effects.

⚠️ Educational research information only — not medical advice. Many peptides are sold strictly for laboratory research and are not approved treatments. The evidence scores reflect research interest and strength, not efficacy or safety for any individual. Always consult a qualified professional.